• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用基于神经病理学作为ground truth 的机器学习对认知正常的老年人进行 F-Flutemetamol 扫描分类。

Classification of F-Flutemetamol scans in cognitively normal older adults using machine learning trained with neuropathology as ground truth.

机构信息

Laboratory for Cognitive Neurology, KU Leuven, Leuven, Belgium.

Alzheimer Research Centre KU Leuven, Leuven Brain Institute, Leuven, Belgium.

出版信息

Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3772-3786. doi: 10.1007/s00259-022-05808-7. Epub 2022 May 6.

DOI:10.1007/s00259-022-05808-7
PMID:35522322
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9399207/
Abstract

PURPOSE

End-of-life studies have validated the binary visual reads of F-labeled amyloid PET tracers as an accurate tool for the presence or absence of increased neuritic amyloid plaque density. In this study, the performance of a support vector machine (SVM)-based classifier will be tested against pathological ground truths and its performance determined in cognitively healthy older adults.

METHODS

We applied SVM with a linear kernel to an F-Flutemetamol end-of-life dataset to determine the regions with the highest feature weights in a data-driven manner and to compare between two different pathological ground truths: based on neuritic amyloid plaque density or on amyloid phases, respectively. We also trained and tested classifiers based on the 10% voxels with the highest amplitudes of feature weights for each of the two neuropathological ground truths. Next, we tested the classifiers' diagnostic performance in the asymptomatic Alzheimer's disease (AD) phase, a phase of interest for future drug development, in an independent dataset of cognitively intact older adults, the Flemish Prevent AD Cohort-KU Leuven (F-PACK). A regression analysis was conducted between the Centiloid (CL) value in a composite volume of interest (VOI), as index for amyloid load, and the distance to the hyperplane for each of the two classifiers, based on the two pathological ground truths. A receiver operating characteristic analysis was also performed to determine the CL threshold that optimally discriminates between neuritic amyloid plaque positivity versus negativity, or amyloid phase positivity versus negativity, within F-PACK.

RESULTS

The classifiers yielded adequate specificity and sensitivity within the end-of-life dataset (neuritic amyloid plaque density classifier: specificity of 90.2% and sensitivity of 83.7%; amyloid phase classifier: specificity of 98.4% and sensitivity of 84.0%). The regions with the highest feature weights corresponded to precuneus, caudate, anteromedial prefrontal, and also posterior inferior temporal and inferior parietal cortex. In the cognitively normal cohort, the correlation coefficient between CL and distance to the hyperplane was -0.66 for the classifier trained with neuritic amyloid plaque density, and -0.88 for the classifier trained with amyloid phases. This difference was significant. The optimal CL cut-off for discriminating positive versus negative scans was CL = 48-51 for the different classifiers (area under the curve (AUC) = 99.9%), except for the classifier trained with amyloid phases and based on the 10% voxels with highest feature weights. There the cut-off was CL = 26 (AUC = 99.5%), which closely matched the CL threshold for discriminating phases 0-2 from 3-5 based on the end-of-life dataset and the neuropathological ground truth.

DISCUSSION

Among a set of neuropathologically validated classifiers trained with end-of-life cases, transfer to a cognitively normal population works best for a classifier trained with amyloid phases and using only voxels with the highest amplitudes of feature weights.

摘要

目的

生命末期研究已经验证了 F 标记淀粉样蛋白 PET 示踪剂的二元视觉读取作为一种准确的工具,用于确定是否存在神经原纤维缠结淀粉样斑块密度增加。在这项研究中,将测试基于支持向量机(SVM)的分类器的性能,以对抗病理的ground truths,并确定其在认知健康的老年人中的性能。

方法

我们将线性核 SVM 应用于 F-Flutemetamol 生命末期数据集,以确定数据驱动方式中具有最高特征权重的区域,并分别比较两种不同的病理ground truths:基于神经原纤维缠结淀粉样斑块密度或淀粉样相。我们还基于两种神经病理学 ground truths 中每个的最高特征权重的 10%体素,训练和测试了分类器。接下来,我们在一个独立的认知正常老年人的数据集,即 Flemish Prevent AD Cohort-KU Leuven (F-PACK) 中,测试了无症状阿尔茨海默病(AD)阶段的分类器的诊断性能,这是未来药物开发的一个感兴趣的阶段。我们进行了回归分析,比较了两种分类器基于两个病理 ground truths 的每一个的复合感兴趣容积(VOI)中的 Centiloid(CL)值与超平面之间的距离。还进行了接收器操作特征分析,以确定 CL 阈值,该阈值可在 F-PACK 内最佳区分神经原纤维缠结淀粉样斑块阳性与阴性,或淀粉样相阳性与阴性。

结果

分类器在生命末期数据集内表现出足够的特异性和敏感性(神经原纤维缠结淀粉样斑块密度分类器:特异性为 90.2%,敏感性为 83.7%;淀粉样相分类器:特异性为 98.4%,敏感性为 84.0%)。具有最高特征权重的区域与顶叶后扣带回、尾状核、前内侧前额叶以及后下颞叶和下顶叶皮质相对应。在认知正常队列中,基于神经原纤维缠结淀粉样斑块密度训练的分类器的 CL 与到超平面的距离之间的相关系数为-0.66,基于淀粉样相训练的分类器为-0.88。这一差异具有统计学意义。用于区分阳性与阴性扫描的最佳 CL 截止值为不同分类器的 CL=48-51(曲线下面积(AUC)=99.9%),除了基于淀粉样相训练且基于最高特征权重的 10%体素的分类器。该分类器的截止值为 CL=26(AUC=99.5%),这与基于生命末期数据集和神经病理学 ground truths 来区分 0-2 相与 3-5 相的 CL 阈值非常匹配。

讨论

在一组基于神经病理学验证的分类器中,针对使用仅具有最高特征权重的体素训练的基于淀粉样相的分类器,从生命末期病例转移到认知正常人群的效果最佳。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dba/9399207/0184ebe3daba/259_2022_5808_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dba/9399207/b5372a75e000/259_2022_5808_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dba/9399207/826d5eb3f06e/259_2022_5808_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dba/9399207/936a5228b0e4/259_2022_5808_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dba/9399207/8c41f0b929ae/259_2022_5808_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dba/9399207/0184ebe3daba/259_2022_5808_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dba/9399207/b5372a75e000/259_2022_5808_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dba/9399207/826d5eb3f06e/259_2022_5808_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dba/9399207/936a5228b0e4/259_2022_5808_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dba/9399207/8c41f0b929ae/259_2022_5808_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8dba/9399207/0184ebe3daba/259_2022_5808_Fig5_HTML.jpg

相似文献

1
Classification of F-Flutemetamol scans in cognitively normal older adults using machine learning trained with neuropathology as ground truth.使用基于神经病理学作为ground truth 的机器学习对认知正常的老年人进行 F-Flutemetamol 扫描分类。
Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3772-3786. doi: 10.1007/s00259-022-05808-7. Epub 2022 May 6.
2
Binary classification of ¹⁸F-flutemetamol PET using machine learning: comparison with visual reads and structural MRI.¹⁸F-氟噻匹定 PET 采用机器学习进行二分类:与视觉读取和结构 MRI 的比较。
Neuroimage. 2013 Jan 1;64:517-25. doi: 10.1016/j.neuroimage.2012.09.015. Epub 2012 Sep 14.
3
Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.放射性氟 18 标记的氟曲美他胺的 3 期临床试验与神经纤维缠结密度成像。
JAMA Neurol. 2015 Mar;72(3):287-94. doi: 10.1001/jamaneurol.2014.4144.
4
Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.阿尔茨海默病弥散和核心淀粉样-β斑块中 PiB 和 flutemetamol 的死后分析。
Acta Neuropathol. 2020 Oct;140(4):463-476. doi: 10.1007/s00401-020-02175-1. Epub 2020 Aug 9.
5
Visual assessment of [F]flutemetamol PET images can detect early amyloid pathology and grade its extent.[F]氟替美莫 PET 图像的视觉评估可检测早期淀粉样蛋白病理并分级其程度。
Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2169-2182. doi: 10.1007/s00259-020-05174-2. Epub 2021 Feb 22.
6
Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.[11C]匹兹堡化合物B(PiB)与[18F]氟代甲磺酸去甲替林在正常对照者和阿尔茨海默病患者中的定性和定量成像特征比较。
Neuroimage Clin. 2015 Oct 14;9:592-8. doi: 10.1016/j.nicl.2015.10.007. eCollection 2015.
7
Estimation of amyloid distribution by [F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition.[F]氟替美莫 PET 对淀粉样蛋白分布的评估可预测淀粉样 β 蛋白沉积的神经病理学阶段。
Acta Neuropathol. 2018 Oct;136(4):557-567. doi: 10.1007/s00401-018-1897-9. Epub 2018 Aug 19.
8
Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.注射氟曲美他酚 F18 后β-淀粉样蛋白 PET 成像的死后组织病理学基础。
Acta Neuropathol Commun. 2016 Dec 12;4(1):130. doi: 10.1186/s40478-016-0399-z.
9
Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads.对18F-氟代甲基多巴PET活性进行自动定量,以将扫描结果分类为脑淀粉样蛋白阴性或阳性:与视觉图像读取结果的一致性。
J Nucl Med. 2014 Oct;55(10):1623-8. doi: 10.2967/jnumed.114.142109. Epub 2014 Aug 21.
10
Longitudinal changes in F-Flutemetamol amyloid load in cognitively intact APOE4 carriers versus noncarriers: Methodological considerations.载脂蛋白 E4 携带者与非携带者认知正常人群中 F-Flutemetamol 淀粉样蛋白负荷的纵向变化:方法学考虑。
Neuroimage Clin. 2023;37:103321. doi: 10.1016/j.nicl.2023.103321. Epub 2023 Jan 5.

引用本文的文献

1
A practical overview of the use of amyloid-PET Centiloid values in clinical trials and research.淀粉样蛋白PET百分标准值在临床试验和研究中的实际应用概述。
Neuroimage Clin. 2025 Mar 10;46:103765. doi: 10.1016/j.nicl.2025.103765.
2
Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers.阿尔茨海默病神经病理学及其通过体液和影像生物标志物进行的评估。
Mol Neurodegener. 2025 Mar 14;20(1):33. doi: 10.1186/s13024-025-00819-y.
3
Natural language processing-based classification of early Alzheimer's disease from connected speech.

本文引用的文献

1
Changes in the language system as amyloid-β accumulates.随着淀粉样蛋白-β的积累,语言系统的变化。
Brain. 2021 Dec 31;144(12):3756-3768. doi: 10.1093/brain/awab335.
2
Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults.基线认知能力是认知正常的老年人 4 年内认知变化的最佳预测指标。
Alzheimers Res Ther. 2021 Apr 7;13(1):75. doi: 10.1186/s13195-021-00798-4.
3
Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis.基于 ELISA 和 SIMOA 的血浆 Aβ 比值定量比较用于脑淀粉样血管病的早期检测。
基于自然语言处理的早期阿尔茨海默病与连贯言语的分类。
Alzheimers Dement. 2025 Feb;21(2):e14530. doi: 10.1002/alz.14530. Epub 2025 Jan 27.
4
Centiloid recommendations for clinical context-of-use from the AMYPAD consortium.AMYPAD联盟关于临床使用背景的Centiloid建议。
Alzheimers Dement. 2024 Dec;20(12):9037-9048. doi: 10.1002/alz.14336. Epub 2024 Nov 20.
5
Investigating reliable amyloid accumulation in Centiloids: Results from the AMYPAD Prognostic and Natural History Study.在 Centiloids 中探究可靠的淀粉样蛋白沉积:来自 AMYPAD 预后和自然史研究的结果。
Alzheimers Dement. 2024 May;20(5):3429-3441. doi: 10.1002/alz.13761. Epub 2024 Apr 4.
Alzheimers Res Ther. 2020 Dec 5;12(1):162. doi: 10.1186/s13195-020-00728-w.
4
Different aspects of Alzheimer's disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia.阿尔茨海默病相关淀粉样β肽病理学的不同方面及其与淀粉样蛋白正电子发射断层扫描成像和痴呆的关系。
Acta Neuropathol Commun. 2019 Nov 14;7(1):178. doi: 10.1186/s40478-019-0837-9.
5
Centiloid scaling for quantification of brain amyloid with [F]flutemetamol using multiple processing methods.使用多种处理方法,通过[F]氟代甲磺酸去甲肾上腺素进行脑淀粉样蛋白定量的百分度缩放。
EJNMMI Res. 2018 Dec 5;8(1):107. doi: 10.1186/s13550-018-0456-7.
6
Multisite study of the relationships between antemortem [C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology.多中心研究生前 [C]PIB-PET 百分位值与阿尔茨海默病神经病理学死后测量值之间的关系。
Alzheimers Dement. 2019 Feb;15(2):205-216. doi: 10.1016/j.jalz.2018.09.001. Epub 2018 Oct 19.
7
Estimation of amyloid distribution by [F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition.[F]氟替美莫 PET 对淀粉样蛋白分布的评估可预测淀粉样 β 蛋白沉积的神经病理学阶段。
Acta Neuropathol. 2018 Oct;136(4):557-567. doi: 10.1007/s00401-018-1897-9. Epub 2018 Aug 19.
8
Infrequent false positive [F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques.不常见的假阳性[F]flutemetamol PET 信号通过神经原纤维和弥漫性斑块的联合组织学评估得到解决。
Alzheimers Res Ther. 2018 Jun 23;10(1):60. doi: 10.1186/s13195-018-0387-6.
9
PET staging of amyloidosis using striatum.使用纹状体进行淀粉样变性的 PET 分期。
Alzheimers Dement. 2018 Oct;14(10):1281-1292. doi: 10.1016/j.jalz.2018.04.011. Epub 2018 May 21.
10
In vivo staging of regional amyloid deposition.区域淀粉样蛋白沉积的体内分期
Neurology. 2017 Nov 14;89(20):2031-2038. doi: 10.1212/WNL.0000000000004643. Epub 2017 Oct 18.